

5 July 2019

ASX Market Announcements Australian Securities Exchange 20 Bridge Street SYDNEY NSW 2000

By Electronic Lodgement

Paladin Energy Limited (**Paladin** or the **Company**) (ASX:PDN) advises that the attached Appendix 3B is for the issue of Share Appreciation Rights (SARs) to an employee under the Company's Employee Performance Share Rights Plan.

Paladin Energy Ltd

## **Appendix 3B**

# New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 01/07/96 Origin: Appendix 5 Amended 01/07/98, 01/09/99, 01/07/00, 30/09/01, 11/03/02, 01/01/03, 24/10/05, 01/08/12, 04/03/13

Name of entity

Palad	lin Energy Ltd (PDN)	
ABN		
47 06	51 681 098	
We (	the entity) give ASX the following	g information.
	t 1 - All issues ust complete the relevant sections (attac	h sheets if there is not enough space).
1	*Class of *securities issued or to be issued	Share Appreciation Rights
	Number of the control of the control of	
2	Number of *securities issued or to be issued (if known) or maximum number which may be issued	2,500,000

Principal terms of the \*securities (e.g. if options, exercise price and expiry date; if partly paid \*securities, the amount outstanding and due dates for payment; if \*convertible securities, the conversion price and dates for conversion)

Share Appreciation Rights (SARs) are issued under the terms of the company's existing Employee Performance Share Rights Plan as adopted by shareholders on 9 November 2018 (the Plan) for nil consideration. Share Appreciation Rights issued under the Plan are entitlements to acquire a number of Shares equal to the growth in the value of the underlying Shares (if any) upon satisfaction of the relevant vesting conditions and other terms and conditions determined by the Board under the Plan. These Share Appreciation Rights granted under the Plan are subject to the following vesting dates:

- Tranche 1 700,000 SARs will vest 1 July 2020;
- Tranche 2 700,000 SARs will 1 July 2021;
- Tranche 3 1,100,000 SARs will 1 July 2022.

SARs will only vest on the vesting dates if the employee remains employed by Paladin or a subsidiary of Paladin on the vesting Upon vesting of any Rights, the participant will be issued with Shares equal to the value derived by multiplying the number of vested Rights exercised by the relative growth in share price over the deemed exercise price. Relative share price growth is determined by a comparison of the Paladin share price growth with a hurdle share price of 12.26 cents per share (calculated using Volume weighted average price (VWAP) of a Share for the five trading days before the date of exercise). Vested and exercised Share Appreciation Rights will be converted into Paladin ordinary shares. Unvested Share Appreciation Rights which do not meet the vesting conditions or are not exercised within the exercise period will automatically lapse.

Appendix 3B Page 2 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

4 Do the \*securities rank equally in all respects from the \*issue date with an existing \*class of quoted \*securities?

If the additional \*securities do not rank equally, please state:

- the date from which they do
- the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment
- the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment

No - Share Appreciation Rights are a different security from the existing class of quoted securities (ordinary shares) and therefore do not rank equally with them. Share Appreciation Rights do not confer on the holder an entitlement to vote at shareholder meetings, receive dividends or participate in pro-rata equity issues. Paladin shares which are allocated following the vesting and exercise of Share Appreciation Rights will rank equally in all respects with Paladin ordinary shares.

5	Issue	price	or	consid	leration

Nil

6 Purpose of the issue
(If issued as consideration for the acquisition of assets, clearly identify those assets)

The Share Appreciation Rights (SARs) are issued to an executive as per the terms of her appointment to the role. These SARs are issued under the Company's existing Employee Performance Share Rights Plan as adopted by shareholders on 9 November 2018 (the Plan) for nil consideration.

6a Is the entity an \*eligible entity that has obtained security holder approval under rule 7.1A?

No

If Yes, complete sections 6b – 6h in relation to the \*securities the subject of this Appendix 3B, and comply with section 6i

6b The date the security holder resolution under rule 7.1A was passed

n/a

6c Number of \*securities issued without security holder approval under rule 7.1

Nil

6d Number of \*securities issued with security holder approval under rule 7.1A

n/a

Number of *securities issued with security holder approval (specific security holder approval (specific security holder approval (specify date of meeting)  6f Number of *securities issued under rule 7.1A was issue dunder rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the *issue date and both values. Include the source of the VWAP calculation.  6h If *securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements  6i Calculate the entity's remaining issue capacity under rule 7.1 and rule 7.1A – complete Annexure 1 and release to ASX Market Announcements  7 *Issue dates  Note: The issue date may be prescribed by ASX (refer to the definition of issue date in rule 19.12). For example, the issue date for a pro rata entitlement issue must comply with the applicable timetable in Appendix 7A.  Cross reference: item 33 of Appendix 3B.  Number and *class of all *securities quoted on ASX (including the *securities in section 2 if applicable)  Number				
under an exception in rule 7.2  6g	6e	with security holder approval under rule 7.3, or another specific security holder approval	n/a	
7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the *issue date and both values. Include the source of the VWAP calculation.  6h If *securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements  6i Calculate the entity's remaining issue capacity under rule 7.1 and rule 7.1A - complete Annexure 1 and release to ASX Market Announcements  7 *Issue dates  Note: The issue date may be prescribed by ASX (refer to the definition of issue date in rule 19.12). For example, the issue date for a pro rate entitlement issue must comply with the applicable timetable in Appendix 7A.  Cross reference: item 33 of Appendix 3B.  Number †Class  1,752,084,272 Ordinary Shares	6f		2,500,000	
rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements  6i Calculate the entity's remaining issue capacity under rule 7.1 and rule 7.1A – complete Annexure 1 and release to ASX Market Announcements  7 *Issue dates  Note: The issue date may be prescribed by ASX (refer to the definition of issue date in rule 19.12). For example, the issue date for a pro rata entitlement issue must comply with the applicable timetable in Appendix 7A.  Cross reference: item 33 of Appendix 3B.  Number and *class of all *securities quoted on ASX (including the *securities in Appendix 7A).  Number †Class  Number †Class  Number †Class  Number †Class  Number †Class  Number †Class  Norte: The issue date for a pro rate entitlement issue must comply with the applicable timetable in Appendix 7A.  Cross reference: item 33 of Appendix 3B.	6g	7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the tissue date and both values. Include the source of the VWAP	n/a	
issue capacity under rule 7.1 and rule 7.1A – complete Annexure 1 and release to ASX Market Announcements  7	6h	rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to	n/a	
Note: The issue date may be prescribed by ASX (refer to the definition of issue date in rule 19.12). For example, the issue date for a pro rata entitlement issue must comply with the applicable timetable in Appendix 7A.  Cross reference: item 33 of Appendix 3B.  Number and +class of all +securities quoted on ASX (including the +securities in	6i	issue capacity under rule 7.1 and rule 7.1A – complete Annexure 1 and release to ASX Market		
8 Number and +class of all +securities quoted on ASX (including the +securities in large) Ordinary Shares	7	Note: The issue date may be prescribed by ASX (refer to the definition of issue date in rule 19.12). For example, the issue date for a pro rata entitlement issue must comply with the applicable timetable in Appendix 7A.	5 July 2019	
	8	<sup>+</sup> securities quoted on ASX ( <i>including</i> the <sup>+</sup> securities in		

Appendix 3B Page 4 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

9 Number and \*class of all \*securities not quoted on ASX (*including* the \*securities in section 2 if applicable)

Number	+Class
3,835,000	2015 Share appreciation rights (granted 1 November 2015 and 31 March 2016)
1,683,000	2016 Share Appreciation Rights (granted 11 November 2016)
6,567,5000	2018 Share Appreciation Rights (granted 16 April 2018)
5,000,000	Share Appreciation Rights (granted 1 July 2018)
2,500,000	Share Appreciation Rights (granted 1 March 2019)
2,500,000	Share Appreciation Rights (granted 1 July 2019)

Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests) n/a

n/a

## Part 2 - Pro rata issue

11	Is security holder approval required?	n/a
12	Is the issue renounceable or non-renounceable?	n/a
13	Ratio in which the *securities will be offered	n/a
		Г.
14	*Class of *securities to which the offer relates	n/a

15	<sup>+</sup> Record date to determine n/a entitlements	
16	Will holdings on different registers (or subregisters) be aggregated for calculating entitlements?	
17	Policy for deciding entitlements in relation to fractions $n/a$	
18	Names of countries in which the entity has security holders who will not be sent new offer documents  Note: Security holders must be told how their entitlements are to be dealt with.  Cross reference: rule 7.7.	
19	Closing date for receipt of n/a acceptances or renunciations	
20	Names of any underwriters n/a	
21	Amount of any underwriting fee n/a or commission	
22	Names of any brokers to the $n/a$ issue	
23	Fee or commission payable to the broker to the issue	
24	Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of security holders	
25	If the issue is contingent on security holders' approval, the date of the meeting	
26	Date entitlement and acceptance form and offer documents will be sent to persons entitled $n/a$	
27	If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders	
28	Date rights trading will begin (if n/a	

<sup>+</sup> See chapter 19 for defined terms.

Appendix 3B Page 6 04/03/2013

	applicable)	
29	Date rights trading will end	n/a
30	How do security holders sell their entitlements <i>in full</i> through a broker?	n/a
31	How do security holders sell <i>part</i> of their entitlements through a broker and accept for the balance?	n/a
32	How do security holders dispose of their entitlements (except by sale through a broker)?	n/a
33	<sup>+</sup> Issue date	n/a
	<b>3 - Quotation of securitie</b> ed only complete this section if you are a	
34	Type of *securities (tick one)	
(a)	*Securities described in Part	t 1
(b)	*	end of the escrowed period, partly paid securities that become fully paid, en restriction ends, securities issued on expiry or conversion of convertible
Entiti	es that have ticked box 34(a)	
Addi	tional securities forming a nev	v class of securities
Tick to docum	n indicate you are providing the informatents	tion or
35		securities, the names of the 20 largest holders of the the number and percentage of additional *securities
36	+securities setting out the ni 1 - 1,000	y securities, a distribution schedule of the additional umber of holders in the categories
	1,001 - 5,000 5,001 - 10,000	
	10,001 - 100,000 100,001 and over	
	,	

37	A copy of any trust deed for the additional *securities		
Entitie	es that have ticked box 34(b)		
38	Number of *securities for which *quotation is sought	n/a	
39	<sup>+</sup> Class of <sup>+</sup> securities for which quotation is sought	n/a	
40	Do the *securities rank equally in all respects from the *issue date with an existing *class of quoted *securities?	n/a	
	If the additional *securities do not rank equally, please state:  • the date from which they do  • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment  • the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment		
41	Reason for request for quotation now  Example: In the case of restricted securities, end of restriction period	n/a	
	(if issued upon conversion of another *security, clearly identify that other *security)		
	X 1 1 1 1 1 0 0 11	Number	+Class
42	Number and *class of all *securities quoted on ASX (including the *securities in clause 38)	n/a	n/a
		ı	I .

Appendix 3B Page 8 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

#### **Quotation agreement**

- <sup>†</sup>Quotation of our additional <sup>†</sup>securities is in ASX's absolute discretion. ASX may quote the <sup>†</sup>securities on any conditions it decides.
- 2 We warrant the following to ASX.
  - The issue of the \*securities to be quoted complies with the law and is not for an illegal purpose.
  - There is no reason why those \*securities should not be granted \*quotation.
  - An offer of the \*securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any \*securities to be quoted and that no-one has any right to return any \*securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the \*securities be quoted.
- If we are a trust, we warrant that no person has the right to return the \*securities to be quoted under section 1019B of the Corporations Act at the time that we request that the \*securities be quoted.
- We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.
- We give ASX the information and documents required by this form. If any information or document is not available now, we will give it to ASX before †quotation of the †securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

Sign here: Date: 5 July 2019

(Company Secretary)

Print name: Andrea Betti

== == == ==

04/03/2013 Appendix 3B Page 9

<sup>+</sup> See chapter 19 for defined terms.

## Appendix 3B – Annexure 1

## Calculation of placement capacity under rule 7.1 and rule 7.1A for eligible entities

Introduced 01/08/12 Amended 04/03/13

#### Part 1

Rule 7.1 – Issues exceeding 15% of capital		
Step 1: Calculate "A", the base figures capacity is calculated	ure from which the placement	
Insert number of fully paid +ordinary securities on issue 12 months before the +issue date or date of agreement to issue	1,712,843,812	
Add the following:	170,373 – App 3B lodged 3 September 2018	
Number of fully paid <sup>+</sup> ordinary securities issued in that 12 month period under an exception in rule 7.2	34,291,724 – App 3B lodged 25 October 2018	
Number of fully paid <sup>+</sup> ordinary securities issued in that 12 month period with shareholder approval	4,778,363 – App 3B lodged 9 January 2019	
Number of partly paid <sup>+</sup> ordinary securities that became fully paid in that 12 month period		
<ul> <li>Note:</li> <li>Include only ordinary securities here – other classes of equity securities cannot be added</li> <li>Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed</li> <li>It may be useful to set out issues of securities on different dates as separate line items</li> </ul>		
<b>Subtract</b> the number of fully paid <sup>+</sup> ordinary securities cancelled during that 12 month period	0	
"A"	1,752,084,272	

Appendix 3B Page 10 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

Step 2: Calculate 15% of "A"			
"B"	0.15		
	[Note: this value cannot be changed]		
<b>Multiply</b> "A" by 0.15	262,812,641		
Step 3: Calculate "C", the amount of 7.1 that has already been used	of placement capacity under rule		
<b>Insert</b> number of <sup>+</sup> equity securities issued or agreed to be issued in that 12 month period <i>not counting</i> those issued:	Nil		
• Under an exception in rule 7.2			
• Under rule 7.1A			
<ul> <li>With security holder approval under rule 7.1 or rule 7.4</li> </ul>			
<ul> <li>Note:</li> <li>This applies to equity securities, unless specifically excluded – not just ordinary securities</li> <li>Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed</li> <li>It may be useful to set out issues of securities on different dates as separate line items</li> </ul>			
"C"	0		
Step 4: Subtract "C" from ["A" x "B"] to calculate remaining placement capacity under rule 7.1			
"A" x 0.15	262,812,641		
Note: number must be same as shown in Step 2			
Subtract "C"	0		
Note: number must be same as shown in Step 3			
<i>Total</i> ["A" x 0.15] – "C"	262,812,641		
	[Note: this is the remaining placement capacity under rule 7.1]		

04/03/2013 Appendix 3B Page 11

<sup>+</sup> See chapter 19 for defined terms.

## Part 2

Rule 7.1A – Additional placem	nent capacity for eligible entities	
Step 1: Calculate "A", the base figure from which the placement capacity is calculated		
"A"	n/a	
Note: number must be same as shown in Step 1 of Part 1		
Step 2: Calculate 10% of "A"		
"D"	0.10	
	Note: this value cannot be changed	
Multiply "A" by 0.10		
Step 3: Calculate "E", the amount of placement capacity under rule 7.1A that has already been used		
<i>Insert</i> number of <sup>+</sup> equity securities issued or agreed to be issued in that 12 month period under rule 7.1A		
<ul> <li>Notes:</li> <li>This applies to equity securities – not just ordinary securities</li> <li>Include here – if applicable – the securities the subject of the Appendix 3B to which this form is annexed</li> <li>Do not include equity securities issued under rule 7.1 (they must be dealt with in Part 1), or for which specific security holder approval has been obtained</li> <li>It may be useful to set out issues of securities on different dates as separate line items</li> </ul>		
"E"	n/a	

Appendix 3B Page 12 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

Step 4: Subtract "E" from ["A" x "D"] to calculate remaining placement capacity under rule 7.1A		
"A" x 0.10		
Note: number must be same as shown in Step 2		
Subtract "E"		
Note: number must be same as shown in Step 3		
<b>Total</b> ["A" x 0.10] – "E"	n/a	
	Note: this is the remaining placement capacity under rule 7.1A	

04/03/2013 Appendix 3B Page 13

<sup>+</sup> See chapter 19 for defined terms.